Cargando…

P1633: OUTCOME OF SURGICAL INTERVENTIONS IN PATIENTS WITH HAEMOPHILIA A AND B TREATED WITH EXTENDED HALF-LIFE (EHL) FACTOR CONCENTRATES IN A SINGLE CENTRE

Detalles Bibliográficos
Autores principales:	Vaide, Ines, Gottstein, Saskia, Kubicek, Cornelia, Orlovich, Maria, Klamroth, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430121/ http://dx.doi.org/10.1097/01.HS9.0000973404.06980.16

Ejemplares similares

Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate(®) P) in patients with haemophilia A
por: Klamroth, Robert, et al.
Publicado: (2014)

1633. Improving the diagnosis of extra-pulmonary tuberculosis (EPTB): experience from north India
por: Sharma, Anchal, et al.
Publicado: (2020)

An imprint method to produce surface asperities for EHL and RCF experiments
por: Everitt, Carl-Magnus, et al.
Publicado: (2020)

Extensor digitorum longus (EDL) to extensor hallucis longus (EHL) tendon transfer for delayed EHL tendon rupture following anterior ankle arthroscopy – Case report
por: Fallah, Jean-Michel, et al.
Publicado: (2023)

P1633: LOW SERUM BDNF LEVELS ARE ASSOCIATED WITH LOWER PLATELETS’ CD62P REACTIVITY AND INCREASED BLEEDING TENDENCY IN PATIENTS WITH GAUCHER DISEASE
por: Azoulay, D., et al.
Publicado: (2022)

Developing a Short Assessment of Environmental Health Literacy (SA-EHL)
por: Rohlman, Diana, et al.
Publicado: (2022)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
por: Ay, Cihan, et al.
Publicado: (2021)

Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B
por: Aiello, Andrea, et al.
Publicado: (2020)

Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update
por: Aiello, Andrea, et al.
Publicado: (2022)

Padua, the cradle of modern medicine: Bernardino Ramazzini (1633–1714) on headaches
por: Zanchin, G.
Publicado: (2005)

Protocol of the baseline assessment for the Environments for Healthy Living (EHL) Wales cohort study
por: Hill, Rebecca A, et al.
Publicado: (2010)

The profile of patients with haemophilia managed at a haemophilia treatment centre in Pretoria, Gauteng
por: Mafisa, Lethukuthula, et al.
Publicado: (2022)

1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody
por: Gidengil, Courtney, et al.
Publicado: (2023)

Approaches to Improvement of Digital Health Literacy (eHL) in the Context of Person-Centered Care
por: Busse, Theresa Sophie, et al.
Publicado: (2022)

LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A
por: Cuesta‐Barriuso, Rubén, et al.
Publicado: (2022)

Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries
por: Lehtinen, Anna‐Elina, et al.
Publicado: (2022)

1633 The Importance of Considering Different Healthcare Settings When Estimating the Incidence of Clostridium difficile
por: Kuntz, Jennifer, et al.
Publicado: (2014)

Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres
por: Di Minno, Matteo Nicola Dario, et al.
Publicado: (2021)

Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?
por: Allard, Quentin, et al.
Publicado: (2020)

Experimental Study on the Effect of Micro-Texture on EHL Point-Contact Film Thickness Subject to Sliding Conditions
por: Sun, Jianxin, et al.
Publicado: (2022)

Exploring the Variability of the Flat Spectrum Radio Source 1633+382. I. Phenomenology of the Light Curves
por: Algaba, Juan-Carlos, et al.
Publicado: (2017)

Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures
por: Kocher, Florian, et al.
Publicado: (2021)

EHLS at School: school-age follow-up of the Early Home Learning Study cluster randomized controlled trial
por: Westrupp, Elizabeth M., et al.
Publicado: (2018)

1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19?
por: Iannantuono, G.M., et al.
Publicado: (2021)

P1734: LESSONS FROM HIV- HAEMOPHILIA CRISIS AND CURRICULAR LEARNING IN POST COVID TIMES
por: Sekhar, M., et al.
Publicado: (2022)

Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
por: Versloot, Olav, et al.
Publicado: (2022)

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates
por: Mancuso, Maria Elisa, et al.
Publicado: (2017)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data
por: Escobar, Miguel A, et al.
Publicado: (2019)

Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
por: Lorenzoni, Valentina, et al.
Publicado: (2018)

P1672: OCCUPATIONAL INTEGRATION OF ADULTS WITH SEVERE HAEMOPHILIA (INTHEMO): A STUDY BASED ON THE FRANCECOAG REGISTRY
por: Nguyen, Ngoc Anh Thu, et al.
Publicado: (2023)

PB2284: PROTECTION OF PATIENTS WITH HEMATOLOGIC MALIGNANCY FROM SEVERE INFECTION DURING PANDEMIA: ESTONIAN TWO CENTRES EXPERIENCE
por: Vaide, I., et al.
Publicado: (2022)

Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy
por: McCall, Michael, et al.
Publicado: (2019)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

Digital single-operator cholangioscopy with EHL as salvage therapy of an internalized and stone-impacted biliary stent 13 years after implantation
por: Loosen, Sven H., et al.
Publicado: (2022)

Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer
por: Choi, Jung-Won, et al.
Publicado: (2019)

Removal of Polytungstate from Mine Wastewater Using a Flat Renewal Membrane Reactor with N1633 as a Carrier
por: Pei, Liang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bvqk1e5747gthd70rha2b4nea0